Recurrence of cervical cancer in mice after selective estrogen receptor modulator therapy.
Ontology highlight
ABSTRACT: Estrogen and its nuclear receptor, estrogen receptor α, are necessary cofactors in the initiation and multistage progression of carcinogenesis in the K14E6/E7 transgenic mouse model of human papillomavirus-associated cervical cancer. Recently, our laboratory reported that raloxifene, a selective estrogen receptor modulator, promoted regression of high-grade dysplasia and cancer that arose in the cervix of K14E6/E7 transgenic mice treated long-term with estrogen. Herein, we evaluated the recurrence of cervical cancer after raloxifene therapy in our preclinical model of human papillomavirus-associated cervical carcinogenesis. We observed recurrence of cervical cancer in mice re-exposed to estrogen after raloxifene treatment, despite evidence suggesting the antagonistic effects of raloxifene
SUBMITTER: Spurgeon ME
PROVIDER: S-EPMC3906488 | biostudies-literature | 2014 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA